Defense Advanced Research Projects AgencyTagged Content List

Restore and Maintain Warfighter Abilities

Relating to the restoration and optimization of human health

Showing 12 results for Health + COVID-19 RSS
The Autonomous Diagnostics to Enable Prevention and Therapeutics (ADEPT) program supports individual troop readiness and total force health protection by developing technologies to rapidly identify and respond to threats posed by natural and engineered diseases and toxins. A subset of ADEPT technologies specifically support use by personnel with minimal medical training, delivering centralized laboratory capabilities even in the low-resource environments typical of many military operations. The program is part of a portfolio of DARPA-funded research aimed at providing options for preempting or mitigating constantly evolving infectious disease threats.
The DoD requires timely and comprehensive threat detection to support overall readiness, counter the spread of disease, and promote stabilization missions. State of the art diagnostic and biosurveillance systems are unable to keep pace with disease outbreaks and fail to support decision-making at the time and place of need. The “Detect It with Gene Editing Technologies” (DIGET) program aims to leverage advances in gene editing technologies to develop field-forward diagnostic and biosurveillance technologies that enable detection of any threat, anytime, anywhere.
Viral pathogens pose a continuous and shifting biological threat to military readiness and national security overall in the form of infectious disease with pandemic potential. Today’s limited vaccines and other antivirals are often circumvented by quickly mutating viruses that evolve to develop resistance to treatments that are carefully formulated to act only specific strains of a virus.
Panacea is a fundamental research program designed to provide novel, multi-target therapeutics that address under-met physiological needs of Department of Defense operators. To do so, the program is applying a systems-pharmacology approach to address the intrinsic complexity of biological processes and unlock more of the potential drug target space in the human proteome. If it succeeds, it will yield new drugs that address some of the challenging physical demands faced by warfighters, including metabolic stress — as with prolonged exertion at high altitude — and activity-related soft tissue injury and resultant pain and inflammation.
The Pandemic Prevention Platform (P3) program aims to support military readiness and global stability through pursuit of novel methods to dramatically accelerate discovery, integration, pre-clinical testing, and manufacturing of medical countermeasures against infectious diseases. P3 confronts the reality that Department of Defense (DoD) personnel are not only deployed around the world for routine operations, but are often among the first responders to outbreaks of emerging or re-emerging disease with pandemic potential (e.g., Ebola). P3 aims specifically to develop a scalable, adaptable, rapid response platform capable of producing relevant numbers of doses against any known or previously unknown infectious threat within 60 days of identification of such a threat in order to keep the outbreak from escalating and decrease disruptions to the military and homeland.